{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:11:36Z","timestamp":1789009896112,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","award":["1U01HL163983"],"award-info":[{"award-number":["1U01HL163983"]}],"id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"ALSAC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007238","name":"Office of Women's Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["1U01HL163983"],"award-info":[{"award-number":["1U01HL163983"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["K23HL146841"],"award-info":[{"award-number":["K23HL146841"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["U01 HL156620\\u201301"],"award-info":[{"award-number":["U01 HL156620\\u201301"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000873","name":"Andrew W. Mellon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008935","name":"Center of Excellence in Regulatory Science and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.03.019","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:50:37Z","timestamp":1774659037000},"page":"778-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-5903","authenticated-orcid":false,"given":"Adetola","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap J.","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"LaBelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tisdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmanan","family":"Krishnamurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-9752","authenticated-orcid":false,"given":"Lydia H.","family":"Pecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-4243","authenticated-orcid":false,"given":"Mary","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Porteus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1070-8486","authenticated-orcid":false,"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-3559","authenticated-orcid":false,"given":"Tami D.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-6290","authenticated-orcid":false,"given":"Mar\u00eda I.","family":"Cancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jtct.2026.03.019_bib0001","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.019_bib0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.019_bib0004","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.019_bib0005","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.03.019_bib0006","series-title":"Presentation at ASH Annual Meeting and Exposition","article-title":"Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: safety and efficacy findings from the ongoing BEACON study","author":"Gupta","year":"2025"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.019_bib0007","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2026.03.019_bib0008","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood.2024024519","article-title":"How I treat sickle cell disease with gene therapy","volume":"144","author":"Sharma","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.019_bib0009","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/pm\/pnaa464","article-title":"Pain experiences of adults with sickle cell disease and hematopoietic stem cell transplantation: a qualitative study","volume":"22","author":"Abu Al Hamayel","year":"2021","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30046","article-title":"Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease","volume":"70","author":"Bakshi","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.019_bib0011","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/ajh.27757","article-title":"Normalization of cerebral hemodynamics after gene therapy in adults with sickle cell disease","volume":"100","author":"Sharma","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.019_bib0013","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.019_bib0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.hemonc.2019.12.006","article-title":"Alternative donor: \u03b1\u03b2\/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease","volume":"13","author":"Foell","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"25","key":"10.1016\/j.jtct.2026.03.019_bib0015","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood.2023023301","article-title":"An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease","volume":"143","author":"Kassim","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical bone marrow transplantation for sickle cell disease","volume":"4","author":"Kassim","year":"2025","journal-title":"NEJM Evid"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.019_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.05.004","article-title":"Female reproductive health outcomes after hematopoietic cell transplantation for sickle cell disease: is reduced intensity better than myeloablative conditioning?","volume":"29","author":"Meacham","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"10.1016\/j.jtct.2026.03.019_bib0018","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2522967","article-title":"Risk of cancer in patients with thalassemia and sickle cell disease: a systematic review","volume":"57","author":"Merolle","year":"2025","journal-title":"Ann Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.019_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J R Soc Med"},{"issue":"15","key":"10.1016\/j.jtct.2026.03.019_bib0021","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1182\/bloodadvances.2024015413","article-title":"To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients","volume":"9","author":"Sharma","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.019_bib0022","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/bloodadvances.2021004232","article-title":"Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease","volume":"5","author":"Leonard","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.019_bib0023","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjh.18311","article-title":"Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease","volume":"198","author":"Sharma","year":"2022","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.019_bib0024","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.3324\/haematol.2019.236182","article-title":"Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor","volume":"105","author":"Uchida","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.019_bib0025","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.25867","article-title":"Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial","volume":"95","author":"Tisdale","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.019_bib0026","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.03.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.70235","article-title":"G-CSF for mobilizing CD34+ cells in individuals with SCD: a word of caution","author":"Sharma","year":"2026","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.jtct.2026.03.019_bib0028","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/bloodadvances.2018016725","article-title":"Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients","volume":"2","author":"Esrick","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.019_bib0029","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/trf.16551","article-title":"Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease","volume":"61","author":"Avecilla","year":"2021","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.019_bib0030","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.15902","article-title":"Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery","volume":"186","author":"Leonard","year":"2019","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.jtct.2026.03.019_bib0031","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-16-2919","article-title":"Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34+ cells in healthy volunteers","volume":"23","author":"Abraham","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2026.03.019_bib0032","article-title":"Motixafortide for hematopoietic stem and progenitor cell mobilization and collection in sickle cell disease","volume":"144","author":"Leonard","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.019_bib0033","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2022.08.003","article-title":"Editing human hematopoietic stem cells: advances and challenges","volume":"25","author":"Bhoopalan","year":"2023","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.019_bib0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jcyt.2018.12.001","article-title":"Chemistry, manufacturing and controls for gene modified hematopoietic stem cells","volume":"21","author":"Soni","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.03.019_bib0035","article-title":"Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up","year":"2020","journal-title":"Guidance for Industry"},{"key":"10.1016\/j.jtct.2026.03.019_bib0036","series-title":"Long term follow-up after administration of human gene therapy products","year":"2020"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41596-020-00431-y","article-title":"Tools for experimental and computational analyses of off-target editing by programmable nucleases","volume":"16","author":"Bao","year":"2021","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.019_bib0038","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0039","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.019_bib0040","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.fertnstert.2020.11.040","article-title":"Ovaries of patients recently treated with alkylating agent chemotherapy indicate the presence of acute follicle activation, elucidating its role among other proposed mechanisms of follicle loss","volume":"115","author":"Shai","year":"2021","journal-title":"Fertil Steril"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.019_bib0041","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13866","article-title":"Alkylating agents-induced gonadotoxicity in prepubertal males: insights on the clinical and preclinical front","volume":"17","author":"Sriram","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.019_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.05.003","article-title":"Effect of busulfan and treosulfan on gonadal function after allogeneic stem cell transplantation in children and adolescents with nonmalignant diseases is not exposure-dependent","volume":"29","author":"van der Stoep","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.019_bib0043","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/jcm11092318","article-title":"Fertility after curative therapy for sickle cell disease: a comprehensive review to guide care","volume":"11","author":"Nickel","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.019_bib0044","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(22)00353-2","article-title":"Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care","volume":"10","author":"Pecker","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0045","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1182\/hematology.2022000382","article-title":"Incorporating gonadal health counseling into pediatric care of sickle cell patients","volume":"2022","author":"Meacham","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.019_bib0046","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17474086.2024.2372320","article-title":"Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women","volume":"17","author":"Pecker","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.019_bib0047","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.fertnstert.2019.09.013","article-title":"Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion","volume":"112","year":"2019","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.019_bib0048","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10815-024-03054-4","article-title":"Ovarian tissue cryopreservation for fertility preservation before hematopoietic stem cell transplantation in patients with sickle cell disease: safety, ovarian function follow-up, and results of ovarian tissue transplantation","volume":"41","author":"Missontsa","year":"2024","journal-title":"J Assist Reprod Genet"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.019_bib0049","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.fertnstert.2018.05.016","article-title":"Risks associated with fertility preservation for women with sickle cell anemia","volume":"110","author":"Pecker","year":"2018","journal-title":"Fertil Steril"},{"issue":"26","key":"10.1016\/j.jtct.2026.03.019_bib0050","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/blood.2021014473","article-title":"Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease","volume":"139","author":"Walter","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.019_bib0051","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","year":"2016","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.019_bib0052","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.hoc.2022.07.010","article-title":"Go the distance: reproductive health care for people with sickle cell disease","volume":"36","author":"Pecker","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"17","key":"10.1016\/j.jtct.2026.03.019_bib0053","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1182\/bloodadvances.2022008859","article-title":"Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility","volume":"7","author":"Joseph","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.019_bib0054","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.jtct.2026.03.019_bib0055","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/bloodadvances.2024013275","article-title":"Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity","volume":"8","author":"Bogn\u00e0r","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.019_bib0056","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/FTD.0000000000001107","article-title":"Busulfan interlaboratory proficiency testing program revealed worldwide errors in drug quantitation and dose recommendations","volume":"45","author":"Kweekel","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.019_bib0057","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/FTD.0000000000000862","article-title":"Quality control of busulfan plasma quantitation, modeling, and dosing: an interlaboratory proficiency testing program","volume":"43","author":"McCune","year":"2021","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.019_bib0058","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41591-025-03662-2","article-title":"Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial","volume":"31","author":"Grimley","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.019_bib0059","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jcyt.2024.02.005","article-title":"Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee","volume":"26","author":"John","year":"2024","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.019_bib0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/bloodadvances.2022008137","article-title":"Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease","volume":"7","author":"Leonard","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.019_bib0061","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11916-010-0171-1","article-title":"Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon?","volume":"15","author":"Tompkins","year":"2011","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.019_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.01.001","article-title":"Physical, mental, and social health of adult patients with sickle cell disease after allogeneic hematopoietic stem cell transplantation: a mixed-methods study","volume":"29","author":"Dovern","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.019_bib0063","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbmt.2018.04.002","article-title":"Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.019_bib0064","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bmt.2012.5","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"47","author":"Majhail","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.03.019_bib0065","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.22.01203","article-title":"Secondary neoplasms after hematopoietic cell transplant for sickle cell disease","volume":"41","author":"Eapen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.019_bib0066","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/bloodadvances.2019000839","article-title":"Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases","volume":"4","author":"Kahn","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0067","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.019_bib0068","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.diagmicrobio.2017.05.016","article-title":"False-positive HIV nucleic acid amplification testing during CAR T-cell therapy","volume":"88","author":"Ariza-Heredia","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.019_bib0069","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01420-19","article-title":"False-positive results for human immunodeficiency virus type 1 nucleic acid amplification testing in chimeric antigen receptor T cell therapy","volume":"58","author":"Hauser","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2026.03.019_bib0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2025.5058","article-title":"Advancing a US single-payer model for cell and gene therapy","author":"Brendbekken","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.jtct.2026.03.019_bib0071","first-page":"1413","article-title":"The cell and gene therapy access model","volume":"185","author":"Majerol","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.019_bib0072","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamapediatrics.2024.5100","article-title":"Medicaid and the promise for cure","volume":"179","author":"Miller","year":"2025","journal-title":"JAMA Pediatr"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:59:18Z","timestamp":1782745158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666636726002253"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}